Tacurion Pharma Overview

  • Founded
  • 2013
  • Status
  • Out of Business
  • Latest Deal Type
  • Out of Business

Tacurion Pharma General Information


Developer of a drug compound designed to treat nocturia, the disease of having excessive urination at night. The company's drug compound is a novel, small molecule, selective vasopressin 2 receptor that mimics the action of the natural agent, arginine vasopressin and regulates renal water excretion, enabling patients to avail non fragmented sleep and stay healthy.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Primary Office
  • 520 United States Highway 22
  • Suite 201
  • Bridgewater, NJ 08807
  • United States
+1 (908) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Tacurion Pharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Out of Business 05-Oct-2020 0000 Completed Out of Business
1. Early Stage VC (Series A) 07-May-2013 0000 0000 Completed Clinical Trials - Phase 2
To view Tacurion Pharma’s complete valuation and funding history, request access »